Analyst consensus rating
Lyell Immunopharma Analyst Rating: Buy
Direct answer
Lyell Immunopharma's consensus rating is Buy.
8 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $37.63.
Forecast evidence checked November 21, 2026.
Get free Lyell Immunopharma email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $13.80
- Average price target
- $37.63
- High price target
- $49.00
- Low price target
- $12.00
- Low target gap
- -13%
- Target upside
- +172.6%
- High target gap
- +255.1%
- Target range width
- 268.1%
- Consensus rating
- Buy
- Analysts
- 8
- Evidence date
- November 21, 2026
- Valid through
- November 28, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Lyell Immunopharma?
Lyell Immunopharma has a verified Buy consensus. The same dataset has an average price target of $37.63.
How far are Lyell Immunopharma's low and high targets from the recorded price?
The low target implies -13%, while the high target implies +255.1%.
How many analysts are included in Lyell Immunopharma's consensus?
The verified consensus includes 8 analysts.
How is Lyell Immunopharma's target upside or downside calculated?
The average target of $37.63 is divided by the recorded price of $13.80, then one is subtracted to produce +172.6%. This does not guarantee a future return.
When was Lyell Immunopharma's analyst forecast verified?
The data was verified on 2026-11-21. The dataset is valid through 2026-11-28.